CoChat

Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease

Open access
Luukkonen, Panu K., Tukiainen, Taru, Juuti, Anne, Sammalkorpi, Henna, Haridas, P.A. Nidhina, Niemelä, Onni, Arola, Johanna, Orho-Melander, Marju, Hakkarainen, Antti, Kovanen, Petri T., Dwivedi, Om, Groop, Leif, Hodson, Leanne, Gastaldelli, Amalia, Hyötyläinen, Tuulia, Orešič, Matej, Yki-Järvinen, Hannele · 2020 · JCI Insight
Cited by 99

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Carriers of the hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) gene variant (rs72613567:TA) have a reduced risk of NASH and cirrhosis but not steatosis. We determined its effect on liver histology, lipidome, and transcriptome using ultra performance liquid chromatography-mass spectrometry and RNA-seq. In carriers and noncarriers of the gene variant, we also measured pathways of hepatic fatty acids (de novo lipogenesis [DNL] and adipose tissue lipolysis [ATL] using 2H2O and 2H-glycerol) and insulin sensitivity using 3H-glucose and euglycemic-hyperinsulinemic clamp) and plasma cytokines. Carriers and noncarriers had similar age, sex and BMI. Fibrosis was significantly less frequent while phospholipids, but not other lipids, were enriched in the liver in carriers compared with noncarriers. Expression of 274 genes was altered in carriers compared with noncarriers, consisting predominantly of downregulated inflammation-related gene sets. Plasma IL-6 concentrations were lower, but DNL, ATL and hepatic insulin sensitivity were similar between the groups. In conclusion, carriers of the HSD17B13 variant have decreased fibrosis and expression of inflammation-related genes but increased phospholipids in the liver. These changes are not secondary to steatosis, DNL, ATL, or hepatic insulin sensitivity. The increase in phospholipids and decrease in fibrosis are opposite to features of choline-deficient models of liver disease and suggest HSD17B13 as an attractive therapeutic target.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.132158

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 99

Metadata

Authors
Luukkonen, P. K., Tukiainen, T., Juuti, A., Sammalkorpi, H., Haridas, P. A. N., Niemelä, O., Arola, J., Orho-Melander, M., Hakkarainen, A., Kovanen, P. T., Dwivedi, O., Groop, L., Hodson, L., Gastaldelli, A., Hyötyläinen, T., Orešič, M., & Yki-Järvinen, H.
Venue
JCI Insight
Published
2020-03-12
Volume
5
Issue
5
ISSN
2379-3708 (ISSN-L)
OpenAlex
W3011781546
Cited by
99
References
9
FWCI
9.52
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. https://app.cochat.ai/papers/10.1172/jci.insight.132158
The paper
Luukkonen, P. K., Tukiainen, T., Juuti, A., Sammalkorpi, H., Haridas, P. A. N., Niemelä, O., Arola, J., Orho-Melander, M., Hakkarainen, A., Kovanen, P. T., Dwivedi, O., Groop, L., Hodson, L., Gastaldelli, A., Hyötyläinen, T., Orešič, M., & Yki-Järvinen, H. (2020). Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. JCI Insight. https://doi.org/10.1172/jci.insight.132158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.